Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 99

1.

TEM-184, a Novel TEM-Derived Extended-Spectrum β-Lactamase with Enhanced Activity against Aztreonam.

Piccirilli A, Perilli M, Amicosante G, Conte V, Tascini C, Rossolini GM, Giani T.

Antimicrob Agents Chemother. 2018 Aug 27;62(9). pii: e00688-18. doi: 10.1128/AAC.00688-18. Print 2018 Sep.

2.

E240V substitution increases catalytic efficiency toward ceftazidime in a new natural TEM-type extended-spectrum beta-lactamase, TEM-149, from Enterobacter aerogenes and Serratia marcescens clinical isolates.

Perilli M, Celenza G, De Santis F, Pellegrini C, Forcella C, Rossolini GM, Stefani S, Amicosante G.

Antimicrob Agents Chemother. 2008 Mar;52(3):915-9. Epub 2007 Dec 26.

3.

Ceftazidime and aztreonam resistance in Providencia stuartii: characterization of a natural TEM-derived extended-spectrum beta-lactamase, TEM-60.

Franceschini N, Perilli M, Segatore B, Setacci D, Amicosante G, Mazzariol A, Cornaglia G.

Antimicrob Agents Chemother. 1998 Jun;42(6):1459-62.

4.

Characterization of a new extended-spectrum beta-lactamase (TEM-87) isolated in Proteus mirabilis during an Italian survey.

Perilli M, Segatore B, De Massis MR, Franceschini N, Bianchi C, Rossolini GM, Amicosante G.

Antimicrob Agents Chemother. 2002 Mar;46(3):925-8.

5.
6.

TEM-121, a novel complex mutant of TEM-type beta-lactamase from Enterobacter aerogenes.

Poirel L, Mammeri H, Nordmann P.

Antimicrob Agents Chemother. 2004 Dec;48(12):4528-31.

7.
8.

Evaluation of the NCCLS extended-spectrum beta-lactamase confirmation methods for Escherichia coli with isolates collected during Project ICARE.

Tenover FC, Raney PM, Williams PP, Rasheed JK, Biddle JW, Oliver A, Fridkin SK, Jevitt L, McGowan JE Jr; Project ICARE.

J Clin Microbiol. 2003 Jul;41(7):3142-6.

9.

Biochemical and genetic characteristics of TEM-29B, a novel extended spectrum beta-lactamase.

Bou G, Martínez-Beltrán J, Cerveró G, Pérez-Díaz JC.

FEMS Microbiol Lett. 1999 May 1;174(1):185-90.

10.

Comparative in vitro and in vivo activities of piperacillin combined with the beta-lactamase inhibitors tazobactam, clavulanic acid, and sulbactam.

Kuck NA, Jacobus NV, Petersen PJ, Weiss WJ, Testa RT.

Antimicrob Agents Chemother. 1989 Nov;33(11):1964-9.

11.

Susceptibility to cephalosporin combinations and aztreonam/avibactam among third-generation cephalosporin-resistant Enterobacteriaceae recovered on hospital admission.

Mischnik A, Baumert P, Hamprecht A, Rohde A, Peter S, Feihl S, Knobloch J, Gölz H, Kola A, Obermann B, Querbach C, Willmann M, Gebhardt F, Tacconelli E, Gastmeier P, Seifert H, Kern WV; DZIF-ATHOS Study Group.

Int J Antimicrob Agents. 2017 Feb;49(2):239-242. doi: 10.1016/j.ijantimicag.2016.10.013. Epub 2016 Nov 28.

PMID:
27939093
12.

Comparative assessment of inoculum effects on the antimicrobial activity of amoxycillin-clavulanate and piperacillin-tazobactam with extended-spectrum beta-lactamase-producing and extended-spectrum beta-lactamase-non-producing Escherichia coli isolates.

López-Cerero L, Picón E, Morillo C, Hernández JR, Docobo F, Pachón J, Rodríguez-Baño J, Pascual A.

Clin Microbiol Infect. 2010 Feb;16(2):132-6. doi: 10.1111/j.1469-0691.2009.02893.x. Epub 2009 Jul 15.

13.
15.

Comparative activities of clavulanic acid, sulbactam, and tazobactam against clinically important beta-lactamases.

Payne DJ, Cramp R, Winstanley DJ, Knowles DJ.

Antimicrob Agents Chemother. 1994 Apr;38(4):767-72.

16.

TEM-72, a new extended-spectrum beta-lactamase detected in Proteus mirabilis and Morganella morganii in Italy.

Perilli M, Segatore B, de Massis MR, Riccio ML, Bianchi C, Zollo A, Rossolini GM, Amicosante G.

Antimicrob Agents Chemother. 2000 Sep;44(9):2537-9.

17.

Substitution of Thr for Ala-237 in TEM-17, TEM-12 and TEM-26: alterations in beta-lactam resistance conferred on Escherichia coli.

Giakkoupi P, Hujer AM, Miriagou V, Tzelepi E, Bonomo RA, Tzouvelekis LS.

FEMS Microbiol Lett. 2001 Jul 10;201(1):37-40.

18.

Comparison of antimicrobial activity between ceftolozane-tazobactam and ceftazidime-avibactam against multidrug-resistant isolates of Escherichia coli, Klebsiella pneumoniae, and Pseudomonas aeruginosa.

Alatoom A, Elsayed H, Lawlor K, AbdelWareth L, El-Lababidi R, Cardona L, Mooty M, Bonilla MF, Nusair A, Mirza I.

Int J Infect Dis. 2017 Sep;62:39-43. doi: 10.1016/j.ijid.2017.06.007. Epub 2017 Jun 10.

19.

Supplemental Content

Support Center